期刊文献+

(1R,2S)-2-(3,4-二氟苯基)环丙胺D-扁桃酸盐的合成 被引量:2

Synthesis of(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamine D-Mandelate
原文传递
导出
摘要 邻二氟苯经傅-克酰化、用硼烷在CBS催化下不对称还原、与膦酰基乙酸三乙酯反应得(1R,2R)-2-(3,4-二氟苯基)环丙基甲酸乙酯,氨解后进行霍夫曼降解,最后与D-扁桃酸成盐制得替卡格雷关键中间体(1R,2S)-2-(3,4-二氟苯基)环丙胺D-扁桃酸盐,总收率32%。同法制得其对映异构体(1S,2R)-2-(3,4-二氟苯基)环丙胺L-扁桃酸盐及外消旋体2-(3,4-二氟苯基)环丙胺草酸盐。并建立了(1R,2S)-2-(3,4-二氟苯基)环丙胺D-扁桃酸盐的手性HPLC检测方法,ee值99.9%。 (1R,2S) -2- (3,4-Difluorophenyl) cyclopropylamine [ (1R,2S) -1] D-mandelate, the key intermediate of ticagrelor, was synthesized from 1,2-difluorobenzene via Friedel-Crafts acylation, CBS reduction, cyclopropanation, ammonolysis, Hofmann degradation followed by salt formation with D-mandelic acid with an overall yield of 32%. The enatiomer of (1R,2S)-1 D-mandelate and 1 oxalate were synthesized by the similar procedures, and the analytical method of chiral HPLC was established. The value of enantiomeric excess of (1R,2S)-1 D-mandelate was 99.9%.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2014年第4期315-317,321,共4页 Chinese Journal of Pharmaceuticals
关键词 (1R 2S)-2-(3 4-二氟苯基)环丙胺D-扁桃酸盐 替卡格雷 中间体 合成 手性检测 (1R,2S)-2-(3,4-difluorophenyl)cyclopropylamine D-mandelate ticagrelor intermediate synthesis chiral analysis
  • 相关文献

参考文献6

  • 1霍韶伟,郭晔堃,钟静芬,时惠麟.新型抗血小板药替卡格雷[J].上海医药,2012,33(3):21-23. 被引量:7
  • 2Jean-paul D, Koen P, Marc R. Chemical process for preparation of aromatic cyclopropane esters and amides: WO, 2008018822 EP], 2008-02-14.
  • 3Khile AS, Patel J, Trivedi N, et al. Process for preparation of phenylcyclopropylamine derivatives: WO, 2011132083 EP]. 2011-10-27.
  • 4Masaru M, Tadashi M, Kentaro T, et al. A process for the preparation of optically active cyclopropylamines: WO, 2008018823 [Pl. 2008-02-14.
  • 5Corey E J, Helal CJ. Reduction of carbonyl compounds with chiral oxazaborolidine catalysts: a new paradigm for enantio- selective catalysis and a powerful new synthetic method [J]. Angew Chem Int Ed, 1998, 37 (15): 1986-2012.
  • 6Singh AK, Rao MN, Simpson JH, et al. Development of a practical, safe, and high-yielding process for the preparation of enantiomerically pure trans-cyclopropane carboxylic acid [J]. Org Process Res Dev, 2002, 6 (5) : 618-620.

二级参考文献5

  • 1Ghatak SB, Panchal SJ. Ticagrelor : a novel player in the field of anti-platelet therapy [J ]. J Pharm Res, 2010, 3(6) : 1271-1273.
  • 2Serebruany VL. Adenosine release : a potential explanation for the benefits of ticagrelor in the PLATelet Inhibition and Clinical Outcomes trial [ J ]. Am Heart J, 2011, 161(1) : 1-4.
  • 3Peters G, Robbie G. Single-dose pharmacokinetics and pharmacodynamics of AZD 6140-an oral reversible ADP receptor antagonist [ J ]. Haematologica, 2004, 89(Supp1 7) : 14-15.
  • 4Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD 6140 with aspirin in patients with atherosclerosis : a double-blind comparison to clopidogrel with aspirin [ J ]. Eur Heart J, 2006, 27(9) : 1038-1047.
  • 5余佩毅,郭文.抗血小板新药替卡格雷临床应用争议[J].世界临床药物,2010,31(5). 被引量:5

共引文献6

同被引文献15

  • 1许学农.反式-(1R,2S)-2-(3,4-二氟苯基)环丙胺的制备方法[P].CN103242171A,2013.
  • 2Guile Simon, Astra Charnwood, Bakewell Road, et al. Novel compounds[ P]. WO 99/05 143,1999.
  • 3Gulle Simon, Astra Charnwood, Bakewell Road, et al. Novel triazolor ( 4, 5-D ) pyrimidine compounds [ P]. WO 00/34 283,2000.
  • 4Owen R T, Serradell A N. Therapy P2Yz reptor antag- onist[J]. Drugs of the Future,2007,32(10) :845 -853.
  • 5Rao Tadimeti, Zhang Chengzhi. Cyclopropyl modula- tors of P2Y,2 receptor[P]. WO 2 011 017 108,2011.
  • 6刘效祥,张强,高云,等.一种替卡格雷中间体的制备方法[P].CN102796007A,2012.
  • 7A Clarke, E Jones, U Larsson, et al. Process for preparation of cyclopropy carboxylic acid esters and derivatives[P]. CN 1 431 992A,2001.
  • 8徐颂,于鹏,赵丽嘉,刘永贵,陈常青.盐酸替卡格雷[J].现代药物与临床,2010,25(1):64-66. 被引量:3
  • 9梁大伟(编译),董金华(审校).替格瑞洛(ticagrelor)[J].中国药物化学杂志,2011,21(6):509-510. 被引量:7
  • 10张建水,李晓军,刘烽,潘仙华.(1R,2S)-2-(3,4-二氟苯基)环丙胺的合成[J].精细化工,2013,30(1):64-68. 被引量:2

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部